Zhejiang Huahai Pharmaceutical (600521) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached RMB 2.12 billion, up 10.76% year-over-year; YTD revenue was RMB 7.25 billion, up 16.76% year-over-year.

• Net profit attributable to shareholders in Q3 was RMB 282.7 million, up 85.09% year-over-year; YTD net profit was RMB 1.03 billion, up 42.92%.

• Growth driven by expanded sales network, new business models, and product structure optimization.

Financial highlights

• Basic and diluted EPS for Q3 was RMB 0.19, up 72.73% year-over-year; YTD EPS was RMB 0.71, up 42%.

• Operating cash flow for Q3 was RMB 579.6 million, up 3.29% year-over-year; YTD operating cash flow was RMB 1.88 billion, up 29.32%.

• Gross margin improved due to cost control and scale effects.

• Total assets at Q3-end were RMB 19.56 billion, up 5.14% from year-end 2023.

• Shareholders' equity at Q3-end was RMB 8.79 billion, up 8.86% from year-end 2023.

Outlook and guidance

• Continued focus on sales network expansion, lean management, and new product launches to drive future growth.